CTLA4 and Schwartz-Jampel syndrome: In this FAERS study, the majority of SJS/TEN cases were reported in patients receiving anti-PD-1 inhibitors (211, 1.40%; ROR: 3.07; 95% CI: 2.68–3.52; IC025: 1.39), followed by anti-PD-1/L1 combined chemotherapy (ROR: 3.06; 95% CI: 2.29–4.10; IC025: 1.13) and anti-PD-1/L1 combined with anti-CTLA-4 therapy (ROR: 2.96; 95% CI: 2.22–3.94; IC025: 1.09).